SCHEMBL2991201

SCHEMBL2991201

COc1cc2c(nc1OC)c(-c1cc3cc(F)cnc3n1S(=O)(=O)c1ccc(C)cc1)cn2CCI

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.35
PIM2 Q9P1W9 1/20 0.35
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.33
ALDH3A1 P30838 2/20 0.33
TSHR P16473 1/20 0.33
ALDH1A1 P00352 2/20 0.31
CYP3A4 P08684 1/20 0.31
SCN9A Q15858 5/20 0.31
KDM4E B2RXH2 1/20 0.30
MEN1 O00255 1/20 0.30
ALOX12 P18054 1/20 0.30
NTSR1 P30989 1/20 0.30
KMT2A Q03164 1/20 0.30
ATM Q13315 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
GABRA2 P47869 1/20 0.30
CYP2C8 P10632 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP2C9 P11712 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2986526 0.92 PIM1 (0.35) PIM1PIM2LMNATP53ALDH3A1
SCHEMBL1749068 0.90 TP53 (0.41) PIM1PIM2LMNATP53ALDH3A1
SCHEMBL2991179 0.88 NPC1 (0.36) PIM1PIM2ALDH1A1KDM4EKMT2A
SCHEMBL2992479 0.87 L3MBTL1 (0.39) LMNATP53ALDH3A1TSHRALDH1A1
SCHEMBL2993710 0.87 PIM1 (0.35) PIM1PIM2LMNATP53ALDH3A1
SCHEMBL9987617 0.86 PTGDR2 (0.36) PIM1PIM2LMNATP53ALDH3A1
SCHEMBL9987572 0.86 PIM1 (0.35) PIM1PIM2LMNAALDH3A1TSHR
SCHEMBL2989166 0.83 PIM1 (0.35) PIM1PIM2LMNATP53ALDH3A1
SCHEMBL2990271 0.82 PTGDR2 (0.36) PIM1PIM2LMNATP53ALDH3A1
SCHEMBL2985981 0.82 PIM1 (0.36) PIM1PIM2LMNAALDH3A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1799691-B1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2011-12-21 EP disclosed
US-20100256141-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2010-10-07 US disclosed
US-7786114-B2 Bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-08-31 US disclosed
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-02-21 US disclosed
EP-1799691-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS Aventis Pharma S.A. (FR) 2007-06-27 EP disclosed
WO-2006037875-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2006-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors BRSK2, KSR2, CDK2 PIM1 695/4885PIM2 607/4885LMNA 3052/4885
US-20100256141-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS BRSK2, KSR2, CDK2 PIM1 695/4885PIM2 607/4885LMNA 3052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.